In 2008, an estimated 34billion euros was spent on the drugs problem in the EU. Much more needs to be done - and must be done - in the battle against the EU's drugs problem. The EU must be more effective in its fight against drugs trafficking, and should call on Member States to be more ready to learn from each other's experiences and to encourage cross-border dialogue between their local governments and cities. Following a six month-long inquiry, the Committee agree that the Member States should, as now, retain responsibility for their own drugs policies. They recommend that the new EU Strategy should concentrate on three key areas. Firstly, co-ordination, through Europol, of the fight against drug trafficking ensuring that any new measures actually reduce the supply of drugs and do not merely move trafficking elsewhere. Secondly, improvement of the collection, analysis, evaluation and distribution of information by the European Monitoring Centre. Thirdly, reliance on the EU's public health obligations and use of public health duties to encourage Member States to devote more resources to harm reduction and to engage in dispassionate and evidence-based discussions on how best to treat the possession and use of drugs. The Committee believes that the creation of a new drugs strategy, lasting until 2020, should provide the perfect platform for a wider and better informed public debate on different Member States' policies and approaches
The issue of large-scale cyber-attacks on the internet has moved up the international agenda recently. This inquiry looks at how States and their major organisations can defend themselves and their critical information infrastructures (CIIs) against such attacks. Whilst individual States bear primary responsibility for their critical national infrastructure (CNI), the infrastructures are heavily interdependent. The Internet is a 'global network of networks' and individual States cannot be viewed in isolation. The Committee therefore concludes that continuing intervention at EU level was appropriate and that all Member States have an interest in bringing the defences of the least protected up. The Committee also looked at ENISA, the European Network and Information Security Agency, and they believe that with a widening of its mandate it can play a more significant part in the developments envisaged.
Commentary Policies and laws Responding to drug problems in Europe -- an overview Cannabis Amphetamines, ecstasy, hallucinogens, GHB and ketamine Cocaine and crack cocaine Opioid use and drug injection Drug-related infectious diseases and drug-related deaths New drugs and emerging trends.
Evidence taken before Sub-committee G (Social Policy and Consumer Affairs). Details of the European Commission Green Paper "Improving the mental health of the population" can be be found at http://ec.europa.eu/health/ph_determinants/life_style/mental/green_paper/mental_gp_en.pdf
This annual directory gives contact details for key members of the institutions and agencies of the European Union, including the European Parliament, the Council, and the European Commission, down to the level of heads of basic operational units. Also known as the Inter-institutional directory of the European Union (IDEA), it contains information updated to July 2006, and it supersedes the 2005 edition (ISBN 9278402583) and the July 2005 update (ISBN 9278403024).
Over 50 per cent of all medicines given to children (and about 90 per cent of those given to the newly-born) have never been tested or authorised for use on them. The Committee's report examines the European Commission's proposal to introduce a Regulation (the Clinical Trials Directive) on medicinal products for paediatric use which aims to stimulate the development of medicines for children and lay down rules for testing and approval. Issues discussed include: the need for better regulation of paediatric medicines; the ethical considerations involved in clinical trials on children, including the issue of consent; mechanisms for implementing the Regulation; access to the database of information on clinical trials; the rewards and incentives proposed to stimulate the research and development of medicines; and the legal basis for the regulation under the EC Treaty. The Committee's report recognises the urgent need for effective action at the European level to authorise medicines for paediatric use and gives broad support to the proposed Directive. However, a number of key issues are highlighted, including: the need for improved labelling of medicines; that the guidelines underpinning the Directive should take account of ethical considerations involved to ensure the rights and capacity of children to give informed consent to trials; and concerns are raised about the adequacy of proposed incentive mechanisms.
Thirty-third report of Session 2005-06 : Documents considered by the Committee on 28 June 2006, including: consultation on fisheries management proposals, report, together with formal Minutes
This will help us customize your experience to showcase the most relevant content to your age group
Please select from below
Login
Not registered?
Sign up
Already registered?
Success – Your message will goes here
We'd love to hear from you!
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.